Urgent

Odontogenic infection in the immunocompromised/diabetic

High-risk dental sepsis · Dental & Oral
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Dental and oral infections in diabetic, neutropenic, immunosuppressed or steroid-dependent patients can progress rapidly with blunted clinical signs, atypical organisms and a markedly higher risk of deep space spread, necrotising infection and sepsis. A low threshold for admission and imaging is essential.

Red flags

  • Rapid spread / disproportionate systemic illness
  • DKA or uncontrolled hyperglycaemia with sepsis
  • Black nasal/palatal eschar (mucormycosis)
  • Neutropenic sepsis
  • Airway compromise

Assessment

Differential diagnosis

  • Simple odontogenic abscess
  • Deep neck space infection
  • Necrotising soft-tissue infection (cervicofacial)
  • Invasive fungal infection (mucormycosis) in diabetics
  • Neutropenic oral ulceration/mucositis
  • Ludwig's angina

Investigations

  • Assess immune status (diabetes/HbA1c, neutrophil count, immunosuppressants, HIV)
  • Full sepsis screen: FBC, CRP, U&E, glucose/ketones, lactate, blood cultures
  • Capillary/venous glucose and ketones (DKA risk with sepsis)
  • CT neck with contrast with a low threshold for deep spread
  • Assess airway, trismus, floor of mouth
  • Consider fungal involvement (nasal eschar) in diabetics

Management

  • Resuscitate per sepsis pathway; monitor for DKA/HHS in diabetics
  • Low threshold for IV broad-spectrum antibiotics and early imaging
  • Optimise glycaemic control; treat DKA if present
  • Early surgical source control — drainage and/or extraction without delay
  • Admit with close observation; many need HDU-level monitoring
  • Involve OMFS early; consider microbiology/infectious diseases for atypical organisms
  • Exclude invasive fungal disease in poorly controlled diabetics (urgent ENT/OMFS and antifungals)
  • Review/optimise immunosuppression with the relevant specialty

Drugs & doses

Co-amoxiclav — 1.2 g IV TDS — empirical broad cover
Piperacillin-tazobactam — 4.5 g IV QDS — if severe/neutropenic sepsis
Metronidazole — 500 mg IV TDS — anaerobic cover
Clindamycin — 600 mg IV QDS — penicillin allergy
Liposomal amphotericin B — 5 mg/kg IV daily — if mucormycosis suspected (specialist)

Disposition

Admit for IV antibiotics, early surgical source control and glycaemic optimisation; HDU/ICU and specialist input (OMFS, microbiology, ID) for severe or atypical infection.

Complications & pitfalls

  • Rapidly progressive deep neck infection / necrotising fasciitis
  • Mucormycosis (diabetics)
  • Septic shock and multi-organ failure
  • DKA/HHS
  • Delayed healing

Exam pearls

  • Clinical signs are blunted in the immunocompromised — treat and image earlier than you would otherwise
  • Sepsis can precipitate DKA, and DKA worsens sepsis — check ketones
  • A diabetic with facial infection and a necrotic nasal/palatal lesion needs urgent exclusion of mucormycosis

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.